All In Biotech

NDA 209449 · Cycle

Harliku

Nitisinone · Oral · 4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor

Orphan

Last checked: Nov 20, 2026Latest source record: Jun 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 26, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

15

3 Phase 3, 0 recruiting

FAERS reports

287

178 serious, 35 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 21, 2026.

NITYR ® is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. NITYR is a hydroxyphenyl-pyruvate dioxygenase inhibitor indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. ( 1 )

Mechanism: Nitisinone is a competitive inhibitor of 4-hydroxyphenyl-pyruvate dioxygenase, an enzyme upstream of fumarylacetoacetate hydrolase (FAH) in the tyrosine catabolic pathway. By inhibiting the normal catabolism of tyrosine in patients with HT-1, nitisinone prevents the accumulation of the catabolic intermediates maleylacetoacetate and fumarylacetoacetate. In patients with HT-1, these catabolic intermediates are converted to the toxic metabolites succinylacetone and succinylacetoacetate, which are responsible for the observed liver and kidney toxicity. Succinylacetone can also inhibit the...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 10, 2025 Supplement 18 · Efficacy · priority review OrphanLabelLetter
  • Sep 2, 2020 Supplement 5 · Efficacy LetterLabel
  • Jul 26, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
4 products under this application
  • HARLIKU · NITISINONE 2MG · TABLET, ORAL · Prescription
  • NITYR · NITISINONE 5MG · TABLET, ORAL · Prescription
  • NITYR · NITISINONE 10MG · TABLET, ORAL · Prescription
  • NITYR · NITISINONE 2MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nitisinone" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • liver transplant33
  • off label use32
  • hepatocellular carcinoma22
  • amino acid level increased20
  • product dose omission issue16
  • treatment noncompliance16
  • death14
  • hepatic failure13
  • hepatic cirrhosis12
  • hospitalisation12
  • alpha 1 foetoprotein increased10
  • drug ineffective10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20063
20101
20111
20129
20135
20151
20163
20173
20186
201918
202033
202144
202242
202339
202434
202531
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nityr (Nitisinone)

2024 spending

$41K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$90.84 per unit

View as table
YearSpending
2020$26,872
2021$239,891
2022$0
2023$30,287
2024$40,880

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Cycle · Also marketed as Nityr

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.